Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae

Niclosamide (NIC) has demonstrated promising in vitro antiviral efficacy against SARS-CoV-2, the causative agent of the COVID-19 pandemic. Though NIC is already FDA-approved, administration of the currently available oral formulation results in systemic drug levels that are too low for the inhibitio...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunaugh, Ashlee D., Seo, Hyojong, Warnken, Zachary, Ding, Li, Seo, Sang Heui, Smyth, Hugh D. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877651/
https://www.ncbi.nlm.nih.gov/pubmed/33571320
http://dx.doi.org/10.1371/journal.pone.0246803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877651/
https://www.ncbi.nlm.nih.gov/pubmed/33571320
http://dx.doi.org/10.1371/journal.pone.0246803

Ejemplares similares